Percutaneous Coronary Intervention PharmacologyFrom a Triangle to a Square*
Harold L. Dauerman, MD, FACC1,*
University of Vermont College of Medicine, Burlington, Vermont.
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 PCI Pharmacology Trials: From the Triple to the Quadruple End Point
The current meta-analysis suggests that the primary end point of percutaneous coronary intervention (PCI) pharmacology trials needs revision. Instead of a triple end point—death, asymptomatic creatine kinase-myocardial band (CK-MB)/symptomatic myocardial infarction (MI), and target vessel revascularization (TVR)—future trials might focus on the quadruple end point, which includes the mortality risk of major bleeding. GPI = glycoprotein IIb/IIIa inhibitor.
|
|
|
